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there were no new ESBL colonizations in patients. This coincided with 
the disappearance of ESBL strains from all sinks.
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Introduction Sepsis may cause mitochondrial dysfunction. The 
renin–angiotensin system (RAS) activity is increased in sepsis, and 
can interfere with the mitochondrial function either directly or by 
modifying hemodynamics. We studied the eff ects of ACE inhibition 
by enalapril on hemodynamics and hepatic mitochondrial function in 
sepsis. Two septic groups without enalapril and with diff erent blood 
pressure targets served as controls.
Methods Sepsis (fecal peritonitis) was induced in 24 anesthetized, 
mechanically ventilated pigs (40.1 ± 2.1 kg), divided into three groups 
(n = 8 for each): ENL (enalapril pretreatment for 7 days and at 0.005 to 
0.02  mg/kg/hour during the study; MAP target 75 to 85  mmHg), ML 
(target MAP 50 to 60 mmHg), and MH (target MAP 75 to 85 mmHg). 
Hemodynamic support with fl uids, norepinephrine (NE; maximum 
dose 5,000  μg/hour), and antibiotics were started after 12  hours of 
peritonitis and continued for 48 hours.
Results All enalapril pigs received the maximum NE dose without 
reaching the target MAP. Enalapril resulted in lower MAP, higher 
CO, and transiently increased regional blood fl ows (Table  1). Fluid 
administration and urinary output were similar among groups. Liver 
mitochondrial respiration was reduced (State 3, State 4) in the enalapril 
group. One animal died in each ML and enalapril group.
Conclusion Enalapril enhances cardiac output and early regional blood 
fl ows in sepsis despite lower MAP, and reduces liver mitochondrial 
respiration, suggesting that RAS is involved in the hemodynamic and 
metabolic changes in sepsis.
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Introduction The present study investigated the eff ects of a single 
dose of intraperitoneal (i.p.) IgG and IgGAM administration on various 
behavioral alterations in a cecal ligation perforation (CLP)-induced 
sepsis model in rats.
Methods Female Wistar albino rats (200 to 250 g) were divided into fi ve 
groups (n = 8): a naive Control group, a Sham operated group receiving 
conventional antibiotic treatment, a CLP group receiving CLP procedure 
and conventional antibiotic treatment, and IgG and IgGAM groups 
which were also applied 1 g/kg, i.p. IgG and IGAM therapy 5 minutes 
after the CLP procedure. Ten, 30 and 60 days after the surgery, animals 
underwent three behavioral tasks: an open fi eld test to evaluate the 
locomotor activity, an elevated plus maze test to measure the level of 
anxiety, and a forced swim test to assess the possible depressive state. 
The results acquired from these tests were used to estimate the eff ect 
of immunoglobulin therapy on behavioral changes in CLP-induced 
sepsis in rats.
Results In the open fi eld test, the CLP group showed a signifi cant 
decrease in total squares passed on days 10 and 30. Similarly, total 
numbers of rearing and grooming were dramatically decreased in the 
CLP group in comparison with control and sham groups (P  <0.005). 
In the elevated plus maze test, the number of entries to open arms 
decreased in the CLP group. In the forced swim test, there was a 
tendency for increase in immobility time in the CLP group, although 
the data were statistically insignifi cant. All of these values which were 
indicating the importance of behavioral alterations were improved on 
day 60. Immunoglobulin therapy prevented the occurrence of these 
behavioral changes. Especially, animals in the IgGAM group conserved 
the values quite near to those of the control group in measured 
parameters.
Conclusion Sepsis, even though it has been treated with conventional 
antibiotics, caused a negative eff ect on behavioral parameters. In this 
study, IgG and IgGAM treated animals in the presence of CLP did not 
show these behavioral changes. Therefore our results suggest that 
a single dose of i.p. IgG and IgGAM treatment, which was applied 
immediately after the sepsis procedure, prevents behavioral defects 
observed following sepsis.
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Introduction Thrombomodulin is an endothelial cell cofactor and 
glycoprotein for thrombin-catalyzed activation of protein C. A recom-
binant human soluble thrombomodulin (rhsTM) has been recently 
developed, and this new agent has a unique amino-terminal structure 
exhibiting anti-infl ammatory activity including sequestraction and 
cleavage of high-mobility group box 1(HMGB-1).
Methods In this study, 13 patients with septic disseminated intravascular 
coagulation (DIC) were treated with rhsTM, which is Recomodulin® Inj. 
12800 (Asahi Kasei Pharma Co., Tokyo, Japan). Patients with septic DIC 
were treated with 130 to 380 U/kg/day.
Results There were signifi cant results for improvement of APACHE 
II score and DIC diagnostic criteria score for critically ill patients after 
treatment using rhsTM (P <0.01). Improvement for platelet count and 
D-dimer level were also observed in this study (P  <0.05). Activation 
of antithrombin (AT) also was signifi cantly increased after treatment 
(P <0.05). Hospital mortality was 15.4% in this study.
Conclusion The rhsTM might be one of most important endogenous 
regulators of coagulation, acting as the major inhibitor of thrombin as 
well as AT III. This new agent may play an important role in treatment 
for septic DIC.
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Introduction Antithrombin III (AT III) has been known to contribute to 
anti-infl ammatory response as well as its anticoagulation. Our previous 
Table 1 (abstract P57). Hemodynamic variables, among times and groups
       P
 BL R0h R12h R24h R36h R48h (time×group)
MAP (ENL/MH/ML)  66 (9)/72 (15)/ 65 (11)/73 (10)/ 57 (4)/82 (6)/ 58 (8)/78 (6)/ 56 (12)/80 (5)/ 56 (11)/79 (9)/ 0.003
 65 (9) 81 (16) 72 (13) 67 (12) 61 (6) 56 (13) 
CO (ENL/MH/ML)  106 (13)/89 (7)/ 92 (17)/67 (11)/ 169 (16)/95 (19)/ 187 (22)/129 (28)/ 161 (25)/139 (32)/ 157 (37)/140 (21)/ <0.0001
 105 (13) 88 (22) 104 (13) 143 (31) 145 (13) 150 (18) 
Carotid fl ow (ENL/MH/ML) 6 (2)/7 (2)/7 (2) 5 (1)/4 (1)/5 (2) 10 (3)/5 (1)/6 (2) 10 (3)/8 (1)/9 (2) 8 (2)/8 (2)/8 (2) 8 (3)/8 (2)/8 (2) <0.0001
Femoral fl ow (ENL/MH/ML) 4 (1)/3 (1)/4 (2) 2 (1)/2 (0)/2 (1) 4 (1)/2 (1)/2 (0) 4 (1)/3 (1)/3 (1) 3 (1)/3 (1)/4 (1) 3 (2)/3 (1)/4 (1) 0.004
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study showed AT III defi ciency happened in the early stage of sepsis 
with no relation to DIC status. However, whether AT III concentrate 
is a benefi cial therapy or not for septic patients is controversial. 
Our hypothesis is that AT III concentrate may have effi  cacy as anti-
infl ammation for sepsis.
Methods From January 2009 to December 2011, adult septic patients, 
whom were given AT III concentrate in our medico-surgical ICU, were 
included in this study. AT III concentrate was administered 30 to 60 U/kg 
intravenously every 24 hours for 3 days in the patients with DIC status 
and AT III defi ciency. Between before and after the AT III concentrate 
therapy, WBC (/mm3), CRP (mg/dl), platelet (×104/μl), PT (seconds), 
fi brinogen (mg/dl), FDP (μg/ml), SOFA score and DIC score were 
evaluated. Values are expressed as mean ± SD. Data were analyzed by 
Wilcoxon signed-rank test. P <0.05 was considered signifi cant.
Results There were 85 patients (52 men, 33 women; age range 19 to 
92 years (mean 69.0  ±  16.9)), and the mortality rate was 27.1% and 
APACHE II score was 20.1  ±  7.6. WBC, CRP, PT and SOFA score were 
signifi cantly improved after AT III concentrate therapy (13,176 ± 9,400 
vs. 11,693  ±  7,089, P  = 0.011, 15.9 vs. 13.3, P  = 0.0015, 16.5  ±  4.4 vs. 
15.9 ± 5.9, P = 0.0045, and 9.7 ± 3.8 vs. 8.6 ± 4.6, P = 0.01, respectively). 
Platelet was signifi cantly decreased (11.7 ± 9.7 vs. 10.6 ± 9.0, P = 0.028), 
while there were no signifi cant diff erences in fi brinogen, FDP and 
DIC score (387.3  ±  202.6 vs. 381.8  ±  163.2, P  = 0.088, 36.9  ±  52.7 vs. 
28.8 ± 39.9, P = 0.059, and 2.9 ± 1.6 vs. 2.6 ± 1.8, P = 0.25, respectively) 
after the therapy. One week after the therapy, platelet and DIC score 
were signifi cantly improved compared with before the therapy 
(15.6 ± 10.0, P = 0.0036 and 1.8 ± 1.9, P = 0.0041).
Conclusion In the patients with septic DIC, WBC, CRP and SOFA score 
were immediately improved after the AT III concentrate therapy, while 
platelet and DIC score were improved later. AT III concentrate may also 
contribute to anti-infl ammatory for septic DIC with anticoagulation.
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Introduction Sepsis and septic shock are complex infl ammatory 
syndromes. Multiple cellular activation processes are involved, and 
many humoral cascades are triggered. Presumably, endothelial cells 
play a pivotal rule in the pathogenesis of sepsis, not only because 
they may infl uence the infl ammatory cascade but also because, upon 
interaction with excessive amounts of infl ammatory mediators, the 
function of these cells may become impaired. It is likely that a general 
dysfunction of the endothelium is a key event in the pathogenesis 
of sepsis [1]. HMG-CoA-reductase inhibitors have been shown to 
exhibit pronounced immunomodulatory eff ects independent of lipid 
lowering. Most of these benefi cial eff ects of statins appear to involve 
restoring or improving endothelial function [2]. We hypothesize that 
statins can improve endothelial dysfunction in septic patients.
Methods A double-blinded, placebo-controlled, randomized trial 
was undertaken. We enrolled adult patients within 24 hours of severe 
sepsis or septic shock diagnosis and randomized them to placebo or 
atorvastatin 80 mg/day for a short term. Endothelial dysfunction was 
assessed measuring plasmatic levels of IL-6, ET-1, VCAM-1 by ELISA and 
measuring fl ow-mediated vasodilatation of the brachial artery at basal, 
24 and 72 hours after randomization.
Results We studied 47 patients, 24 in the placebo group (mean age 
52 ± 20 years, 29.1% male; APACHE II risk score 23.5 ± 7.3) and 23 in 
the statin group (mean age 49.5 ± 18 years, 53.4% male; APACHE II risk 
score 23 ± 6.9). The baseline characteristics of the placebo group were 
similar to statin patients as well as the mean length of stay in the ICU 
(8.6 ± 7.4 and 9.1 ± 8 days, respectively) and the time on vasopressors 
(49.3 ± 47.1 and 59 ± 91.1 hours, respectively). No signifi cant diff erence 
was observed on the temporal variation of biomarker levels (IL-6, 
VCAM-1, ET-1) between treatment and control groups. The intrahospital 
mortality rate was 26% in the statin group and 45% in the placebo 
group (P = 0.17).
Conclusion Our data showed no benefi t with the use of a potent 
statin acutely in patients with sepsis or septic shock with regards to 
improvement in endothelial function.
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Introduction A novel sorbent hemoadsorption device for cytokine 
removal (CytoSorbents, USA) was developed and successfully tested 
in animal models of sepsis. The experience in the clinical setting is 
still limited to case reports. In this fi rst clinical trial, we tested the 
hypothesis that treatment with sorbent hemoadsorption could safely 
and eff ectively reduce cytokines in septic patients with acute lung 
injury (ALI).
Methods Ventilated patients fulfi lling the criteria for severe sepsis and 
ALI were enrolled in this multicenter randomized, controlled, open-
label study comparing standard of care with or without hemoperfusion 
treatment. Primary endpoints were safety and IL-6 reduction. Treated 
patients underwent hemoperfusion at fl ow rates of ~200 to 300  ml/
minute for 6  hours per day for 7 consecutive days. The overall mean 
reduction in individual plasma cytokines for the control and treatment 
groups during the treatment period was calculated using a generalized 
linear model.
Results Forty-three patients (18 treated, 25 control) completed the 
study and were further analyzed. Incidence of organ dysfunction at 
enrollment (treatment vs. control) was: septic shock (94% vs. 100%, 
P = 0.42), acute respiratory distress syndrome (67% vs. 56%, P = 0.33), 
and renal failure (39% vs. 24%, P  = 0.54). During 115 treatments no 
serious device-related adverse events occurred. On average, there 
were no changes in hematology and other blood parameters except 
for a modest reduction in platelet count (<10%) and albumin (<5%) 
with treatment. Hemoperfusion decreased IL-6 blood concentration 
signifi cantly (–49.1%, P  = 0.01), with similar reductions of MCP-1 
(–49.5%, P  = 0.002), IL-1ra (–36.5%, P  = 0.001), and IL-8 (–30.2%, P  = 
0.002). The 28-day mortality (28% vs. 24% control, P  = 0.84) and 60-
day mortality (39% vs. 32% control, P = 0.75) did not diff er signifi cantly 
between the two studied groups.
Conclusion In this fi rst clinical study of a novel sorbent hemoadsorption 
device in patients with severe sepsis and ALI, the device appeared to 
be safe and decreased the blood concentration of several cytokines. 
Further research is needed to study the eff ect of the device on the 
clinical outcome of septic patients.
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Introduction Renal failure is an important complication of sepsis and 
CRRT with adsorbing membranes may be useful in this clinical setting 
[1]. The aims of the study in septic/septic shock patients are to evaluate: 
the safety of a new hemofi lter membrane oXiris with adsorbing 
properties and anti-endotoxin activity; the renal and hemodynamic 
Critical Care 2013, Volume 17 Suppl 2 
http://ccforum.com/supplements/17/S2
S22
